Rajesh Jain

Dr. Rajesh Jain

Jain hospital & Research Centre Pvt Ltd, Kanpur, India
orcid
Consultant Jain hospital & Research Centre Pvt Ltd; Chair Di...

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2021 in Medicina
Verified
Journal Article
Open access
PDF file
UTUDAY THANAWALA
UDAY THANAWALA
HDHema Divakar
Hema Divakar
Rajesh JainRajesh Jain
Rajesh Jain
MAMukesh M. Agarwal
Mukesh M. Agarwal
The worldwide epidemic of diabetes mellitus and hyperglycemia in pregnancy (HIP) presents many challenges, some of which are country-specific. To address these specific problems, parochial resolutions are essential. In India, the government, by working in tandem with (a) national groups such as the Diabetes in Pregnancy Study Group of India, and (b) global organizations such as the International Diabetes Federation, has empowered the medical and paramedical staff throughout the country to manage HIP. Additionally, despite their academic university backgrounds, Indian health planners have provided practical guidelines for caregivers at the ground level, who look up to these experts for guidance. This multipronged process has helped to negotiate some of the multiple problems that are indigenous and exclusive to India. This review traces the Indian journey to manage and prevent HIP with simple, constructive, and pragmatic solutions.
1

14 November 2022 in Cureus
Verified
Journal Article
Open access
VSV Seshiah
V Seshiah
SBS C. Bronson
S C. Bronson
VBV Balaji
V Balaji
Rajesh JainRajesh Jain
Rajesh Jain
CAC Anjalakshi
C Anjalakshi
Diabetes mellitus in recent years has become a relentlessly evolving pandemic. Measures for the screening and early detection of diabetes are practiced all around the world. However, considering the ever-increasing magnitude of the problem, the present efforts should especially focus on the primordial prevention of diabetes. A ray of hope for preventing the development of diabetes in an individual arises from the concept that many adult-onset diseases have already been programmed while the individual was still in-utero. In women with hyperglycemia-in-pregnancy, maternal hyperglycemia results in fetal hyperinsulinemia, which leads to increased adiposity in the fetus, and insulin resistance and diabetes in adulthood. We have ventured to point out that the fetal beta-cells start secreting insulin at 10-11 weeks of pregnancy and fetal hyperinsulinemia persists with maternal hyperglycemia, in a pregnant woman who would develop gestational diabetes. Considering the fetal glucose-steal phenomenon and the fetal renal threshold for glucose, we have suggested a two-hour post-prandial blood-glucose (PPBG) value of >110 mg/dL as the cut-off for the prediction of gestational diabetes in the early weeks of pregnancy. Furthermore, we have emphasized the use of metformin in addition to medical nutrition therapy in the early weeks to maintain PPBG around 110 mg/dL to prevent gestational diabetes. In this paper, we recommend early, universal screening of all pregnant women during the early weeks of the first trimester and put forward that a two-hour PPBG of >110 mg/dl during the 8th-10th week of pregnancy would predict the risk of gestational diabetes in the pregnant woman. We suggest early testing and intervention to prevent the development of fetal hyperinsulinemia as a primordial prevention approach for diabetes.

15 December 2022 in Cureus
Verified
Journal Article
Open access
Rajesh JainRajesh Jain
Rajesh Jain
NBNatrajan Bhavatharini
Natrajan Bhavatharini
TSThangavel Saravanan
Thangavel Saravanan
VSVeeraswamy Seshiah
Veeraswamy Seshiah
NJNishchal Jain
Nishchal Jain
The major trials, e.g., EMPA-REG OUTCOME, CANVAS, and CREDENCE, showed the renal and cardiovascular benefit of sodium-glucose transport protein 2 (SGLT2) inhibitors. The SGLT2 inhibitors, Empagliflozin, Dapagliflozin, and Canagliflozin, have shown no significant adverse renal effects. Still, our patients with type 2 diabetes on Remogliflozin, a type of SGLT2 inhibitor approved in India for the treatment of diabetes, seems to cause acute tubular necrosis as confirmed by clinical and pathological evidence in our study. The two critical findings in our research include a consistent rise in hs-CRP and a pathologist's biopsy report, excluding other causes. Therefore, we need sizeable cardiovascular-renal outcome trials to ascertain the safety of Remogliflozin in future studies.

28 March 2024 in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
GAGeethalakshmi A.
Geethalakshmi A.
SSSaraswathi S.
Saraswathi S.
KKKalaivani K.
Kalaivani K.
ACAnjalakshi C.
Anjalakshi C.
Rajesh JainRajesh Jain
Rajesh Jain
SVSeshiah V.
Seshiah V.
Background: The present study aimed to evaluate if postpartum gestational diabetes mellitus (GDM) screening can be performed during immediate post-delivery 72 hrs instead of six weeks postpartum for follow-up. Methods: Total 150 GDM patients were included. The sample size was calculated as 150 with Nimaster2.0 software. GDM patients are enrolled after meeting the exclusion criteria for the study. The GDM diagnosis was made by DIPSI test and treated as per guidelines. After delivery, the Dipsi test was done on PND-3 (PP1). Furthermore, all were kept on LSM irrespective of the glycaemic level DIPSI test was repeated in all Patients after 45 days (PP2). Results: All 150 patients had a DIPSI test on 3rd day post-partum (PP1) and repeat test at 45 days (PP2)., Of these, 60 patients (40%) showed negative DIPSI test on P1 and all remained in Group 1, with 63 patients having negative DIPSI test on PP2. 50 patients (33.3%) had blood glucose between 140-199 mg (Group 2) on PP1 and increased to 53 patients in PP2 in 45 days. 40 patients had diabetic (26.6%) value (Group 3) in PP1, and out of them 34 (22.6%) remained in group 3 in PP2 after 45 days post-partum. Conclusions: This pilot study shows that nearly 60% of the GDM patient have either IGT or diabetic value following delivery on 3rd day of PP1 and almost similar results in PP2. Hence, we can do the postpartum screening on the postpartum 3rd day and need not wait for 6 wks when more than 50% is lost for follow-up. This study shows among GDM 60% of them have underlying beta cell dysfunction.

30 October 2024 in Diabetes Asia Journal
Verified
Journal Article
Open access
Rajesh JainRajesh Jain
Rajesh Jain
GCGwendolyn Carleton
Gwendolyn Carleton
AEAnna Anna Knauer Elley
Anna Anna Knauer Elley
SOSusanne Olejas
Susanne Olejas
ACAmit Chauhan
Amit Chauhan
Introduction: In 2019, the global prevalence of diabetes was estimated at 9.3%, affecting approximately 463 million people. This figure is projected to rise to 10.2% (about 578 million) by 2030 and 10.9% (around 700 million) by 2045. Diabetes is more common in urban areas (10.8%) than in rural areas (7.2%), and it is also more prevalent in high-income countries (10.4%) compared to low-income countries (4.0%). Alarmingly, nearly half of the individuals living with diabetes, 50.1%, are not aware that they have the condition. In addition, the global prevalence of impaired glucose tolerance was estimated to be 7.5% (approximately 374 million) in 2019, with projections indicating a rise to 8.0% (about 454 million) by 2030 and 8.6% (around 548 million) by 2045

30 October 2024 in Diabetes Asia Journal
Verified
Journal Article
Open access
Rajesh JainRajesh Jain
Rajesh Jain